Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
|Articles|December 17, 2013
Results of the SWOG S0500 Trial
Author(s)Brian Leyland-Jones, MBBS, PhD
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer.
Advertisement
Clinical Pearls
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer. Results of the trial were presented at the 2013 San Antonio Breast Cancer Symposium.
- The trial set out to determine whether CTC levels could be used to guide the frontline treatment of metastatic breast cancer
- It was hypothesized that those patients who maintained a high level of CTCs would do badly
- Patients with low CTC levels before and after chemotherapy did best
- Patients with elevated CTC levels before chemotherapy but lower levels after chemotherapy did moderately well
- Patients with elevated CTC levels before and after chemotherapy did poorly
- This trial demonstrated how dramatic the differences were in prognosis amongst the three groups
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5